D'Amico Risk Classification for Prostate Cancer
Stratifies prostate cancer risk into low, intermediate, and high categories based on PSA, Gleason score, and clinical T stage. Widely used to guide initial treatment decisions.
Score interpretation
D'Amico Low Risk — PSA ≤10, Gleason ≤6, T1–T2a. 5-year PSA failure rate ~25%.
→ Active surveillance option for suitable patients; or definitive therapy (prostatectomy/radiotherapy) — shared decision-making
D'Amico Intermediate Risk — PSA 10–20, Gleason 7, or T2b. 5-year PSA failure rate ~50%.
→ Radical prostatectomy or radiotherapy ± short-term ADT (4–6 months); urology/oncology MDT
D'Amico High Risk — PSA >20, Gleason 8–10, or T2c–T3. 5-year PSA failure rate ~75%.
→ Radiotherapy + long-term ADT (2–3 years); radical prostatectomy with extended pelvic lymph node dissection; systemic staging; consider clinical trial
Interpretation bands for the D'Amico Risk. Apply clinical judgement and local guidance.
References
- D'Amico AV et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969–974.
Related
Curated clinical cross-links plus same-class fallbacks.
- Gleason Score / Grade Group for Prostate Cancer · Prostate Cancer
- Prostate Cancer Risk Stratification (NICE / EAU) · Prostate Cancer
- UCSF-CAPRA Score for Prostate Cancer · Prostate Cancer
- PSA Doubling Time (PSADT) Calculator · Prostate Cancer
- PSA Velocity and PSA Density · Prostate Cancer
- D'Amico Risk Stratification for Localised Prostate Cancer · Prostate Cancer
- Cetuximab · Anti-EGFR Monoclonal Antibody — Head and Neck Cancer
- Cisplatin · Platinum Chemotherapy — Head and Neck Cancer
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Atorvastatin (CKD Cardiovascular Risk) · Cardiovascular Risk in CKD
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.